How we started

On the 8th of August, 1988, several prominent doctors and surgeons believed that conventional drugs were lacking in potency and believed that only a quality drug will improve the welfare of mankind.

 

Concerned for their patients’ health and wellbeing, the founders decided to establish a state of the art pharmaceutical manufacturing facility to create drugs in accordance to their own strict specifications. As a result of such strong ideals and a passion for welfare, Fahrenheit was born. As such, the visions of our founders can be reflected in the company’s name, PT. Pratapa Nirmala. Adopted from ancient Sanskrit, Pratapa translates to glory while Nirmala means pure. In short, to achieve glory, we need to get customer respect and loyalty, and the only way to achieve this is to sell our products in its purest form, the highest possible quality.

 

Fahrenheit’s first manufacturing facility was constructed in a major industrial complex in Tangerang, West Java on two hectares of land. Its first commercial batch consisted of cardiovascular drugs and vitamins prepared in simple oral forms. Since then, the plant’s technology and facilities have been continuously upgraded several times to offer only the highest quality products.

In 1994, Fahrenheit expanded its manufacturing and added oral and injectable Cephalosporine to its lineup. Another expansion was completed in 1995 to accommodate the manufacturing of small volume parenteral (SVP) and ophthalmic products. Despite the economic crisis of 1998 in Asia, the company aggressively expanded its manufacturing capabilities to develop large volume parenteral products with a focus on antibiotics. Our investment in oral and injectable hormone contraceptive products bore fruit in 2004. A new facility was constructed to accommodate for increased demand of oral and injectable Cephalosporine in 2010.

By 2012, the company invested in a larger SVP plant complete with a lyophilized facility. We finished construction of a larger facility for LVP products in 2015 and we are currently building an additional plant for our oral dosage preparations due to be finished in 2017. All of Fahrenheit’s practices comply with the GMP International Standards to develop an assortment of ethical products for cardiovascular, hematopoietic, respiratory, metabolic, alimentary, genitourinary systems, antibiotics and vitamins from simple oral forms two injectable forms including IV solutions. With the company’s wide range of capabilities, it has positioned itself as a major branded generic manufacturing company in Indonesia focusing on specialty products.

 

PT. Yarindo Farmatama and PT. Dian Langgeng Pratama

 

The financial crisis of 1998 in Indonesia saw a shift in market growth from branded generic market to the lower generic market. Seeing this as an opportunity, Fahrenheit decided to enter the market by establishing its subsidiary generic manufacturing company, PT. Yarindo Farmatama, located in Serang, Banten.

In over five years since its inception, PT. Yarindo Farmatama has enjoyed a growth rate of more than 50% annually. Both companies have given an unsurpassed competitive advantage as they have been able to penetrate aggressively in the ethical market. As a result of such a strong growth in the medical segment, Fahrenheit decided to establish another subsidiary company, PT. Dian Langgeng Pratama to promote medical equipment. At this moment, PT. Dian Langgeng Pratama is responsible for marketing and distributing imported medical products. We are able to closely monitor the logistics of these products which require special care and treatment.

However, we won’t stop there as Fahrenheit is still seeking reliable partners to market and distribute its niche medical products. In the near future, PT. Dian Langgeng Pratama is planning to invest in manufacturing facilities for these medical devices. Our expansions and development show Fahrenheit’s deep commitment in the medical market and we are proud to say that more plans for expansion are being constructed to fulfill our passion for growth.

 

PT. Fahrenheit Synthon Pharma (Joint Venture)

For the sake of achieving our vision to be a company that focuses on specialty pharmaceutical products, we have formed a joint venture company called PT. Fahrenheit Synthon Pharma with Synthon BV from the Netherlands. Synthon BV is uniquely established and is highly recognized as a vertically integrated company developing and manufacturing specialty products from active raw materials to its finished formulations. Our manufacturing facility is located at Kawasan Industri Milennium, Tangerang which will product high potent oral products used in the field of oncology.

With this company, this unique manufacturing capability will provide Fahrenheit with the opportunity to penetrate the fast growing specialty segment of oncology as well as neurology and urology segments. Together with Synthon BV, Farhenheit has the potential to become a market leader in the specialty segment. Our joint venture company will compete in the specialty segment which has been historically dominated by multinational companies and our job will be to provide alternative prescription medicine for medical doctors and Indonesian patients that has been approved by European standards.

As such, we will be able to reach our vision to be a company that produces specialty pharmaceutical products and our extended range of products will be able to cater to more patients as part of our mission.

Organisational Structure

Partnerships & Joint Ventures

In new markets, we aim to develop a strong formulation and manufacturing capabilities to establish ourselves as early generic players in the market.

In addition, we will increase our business development capabilities to identify new niche market segments. Fahrenheit plans to expand its influence internationally with other pharmaceutical industries, particularly on hospital and niche products. We will create strong bonds with our partners overseas in a way that is beneficial to our partners and to ourselves. Below are some examples as a result of our collaboration

 

  • General inhalation anesthetic
  • Terrell (Isoflurane), launch since 2006
  • Sojourn (Sevoflurane), launch since 2007

 

  • Nano NSAID
  • Zorvolex (nano diclofenac)
     

 

  • Hormonal Therapy
  • Nateran (Exemestane)
     
  • Hepatitis C
  • Hepcinat (Sofosbuvir)
  • Natdac (Daclastavir)
  • Sofosbuvir + Ledispavir (under registration)
  • Agrylin (Anagrelide)
  • Fosrenol (Lanthanum Carbonate)
Marketing

“I do solemnly pledge that I will tell the doctor the truth, the whole truth, and nothing but the truth, that I will make no exaggerated claims of superiority or safety; that I will always give adequate assurance and proof that what I say about a product is true; that I will constantly remind myself that no mediation is 100% effective in all patients and that even a placebo may cause distressing side effect in some patients; and that the difference between the product I am detailing and the product the doctor has been using is much smaller in his eyes than in my own, and any exaggeration in this difference will only serve to confirm previous prescription writing habit. Professionalism belongs to every business level, from the chairman of the board to the operator of the manufacturing equipment. The job itself is not important; it’s how you do it that counts. There is only one way to take pride in what you do: “Do the best job you possibly can”. To do that you have to sort out your priority. By doing so you will be able to improve your skill for the sake of Fahrenheit growth”.

 

 

The medical representatives’ dedication to the above pledge, as well as their desire to promote high value medicine, contribute to the significant sales growth achieved in the recent years. Fahrenheit has enjoyed consistent sales growth due to our hard work in ensuring the highest quality in our products leading to a high level of respect and loyalty among our customers.

As a leading pharmaceutical company in Indonesia, Fahrenheit understands the importance of conducting market surveys to explore new opportunities, evaluate the market, assess customer needs, and study global marketing trends prior to the product launch. This approach ensures the most suitable selection of available resources in order to achieve the best rate of return and achieve our vision of becoming the leading pharmaceutical company in Indonesia focusing on specialty products.

With years of experience in medical training, our marketing team has successfully penetrated the specialty market which has been historically dominated by multinational companies. The team has always, and will continue to spread its influence through medical seminars, promotions, social media, and more. At present, Fahrenheit’s marketing network covers almost all of Indonesia, with 34 bases, 360 Medical Representatives, 146 Supervisors, 36 Regional Sales Managers and 6 Sales Managers. The company’s influence has also spread regionally, with exports to the Philippines, Thailand, Brunei, Timor Leste, Saudi Arabia, Ethiopia, Pakistan, Jordania, Malaysia.

 

Manufacturing

 

In accordance to our vision and mission, we at Fahrenheit believe that our existence, as well as our future, depends entirely on our ability to consistently manufacture products of the highest quality. Therefore, we believe that effective total quality management is; aside from being a basic necessity, also a top priority.

Fahrenheit adheres to the following parameters in manufacturing: the drugs have to be completely safe, they have to be authentic and have the highest purity, and they should have a reputable and reliable efficacy. Fahrenheit has implemented total quality management procedures which adhere to the International GMP Standards and are coordinated from fully equipped, modern laboratories led by highly qualified pharmacists. In addition, the company implements and strictly carries out the ‘World Manufacturing Practice’ which ensures that quality is etched directly into its products.

A Message from the Managing Director

“We consistently provide improvements in product quality and cost reduction through continuous innovation and collaboration to serve customers with products of the highest quality in order to gain their respect and loyalty”

 These words reflect the company’s mission statement since its inception in 1988 and will continue to do so in the coming future. Each and every word in the mission statement has been carefully chosen to reflect our company strategy in order to live up to the expectations and standards envisioned by it.

Tough competition by market globalization drives us to deliver high quality products through innovation that encapsulates new ideas and collaboration to encourage creativity. In addition, Farhrenheit is seeking to expand its lineup by seeking collaboration with partners overseas to develop and distribute licensed new products. Partnership like these allows the construction of distribution networks for the company which can provide us with new opportunities to expand beyond the local market. Together with our local products, Fahrenheit is able to deliver new products and concepts to provide customers with products that meet their needs, keeping in mind the mission statement.

However, the mission statement does not end there. It is carried on in the hearts of people in Fahrenheit, guiding everyone to do their very best for the sake of achieving the company vision and mission. Moreover, as we are rapidly expanding, it is also important that our partners, suppliers and customers are fully aware of the goals of the company and the direction it is taking. As Managing Director of this company, I believe that this brief statement sends an important message to everyone within the organization and to those who interact with Fahrenheit, and we should take pride in this clear statement of direction.

 

Our Vision and Mission

Vision

To become a leading pharmaceutical company in Indonesia that focus on specialty pharmaceutical products.

Mission

To consistently provide improvements in product quality and cost reduction through continuous innovation and collaboration so as to serve customers with products of the highest quality in order to gain their respect and loyalty.

 

Our Corporate Social Responsibility

Our Responsibility

To create products that fulfill safety, efficacy, and quality requirements in accordance to the guidelines set by the international health authorities.

Our Values

H uman resources that are capable and dedicated

E ffecctive and efficient

A micable and harmonious work environment

L earning through experience for the betterment of the company

T horough and detailed

H igh quality

Dr. Januar Widodo Finasm, SpPD, KGH

Dr. Januar Widodo Finasm, SpPD, KGH

Board of Medical Directors

Adi Suherman

Adi Suherman

Director

Thomas C. K.

Thomas C. K.

General Sales Manager OGB-Trading & Contraception

Daniel

Daniel

Finance & Accounting Director

Dr. Antono Tan, FACCm FSCAI, FAMS

Dr. Antono Tan, FACCm FSCAI, FAMS

Board of Medical Directors

Fung Mie

Fung Mie

EDP, Document Center & Compliance Manager

Suparjo

Suparjo

Sales Director Ethical

John

John

Head of Marketing

Dewi Sri Kurniati

Dewi Sri Kurniati

HRD & GA Manager

Peter Sutandar

Peter Sutandar

Managing Director

peter@fahrenheit.co.id

Nofa Sumarwati

Nofa Sumarwati

Acting Business Unit Head OTC

Gunawan Kusuma

Gunawan Kusuma

Deputy Sales Director Ethical

Sonny Langi

Sonny Langi

Manufacturing Director